Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington’s Disease and Tardive Dyskinesia

References

• Stahl SM. Neuronal traffic signals in tardive dyskinesia: not enough “stop” in the motor striatum. CNS Spectr. 2017;22(6):427–434. doi:10.1017/S109285291700061X
   PubMed Web of Science ®Google Scholar
• Frei K. Tardive dyskinesia: who gets it and why. Parkinsonism Relat Disord. 2019;59:151–154. doi:10.1016/j.parkreldis.2018.11.017
   PubMed Web of Science ®Google Scholar
• Wimalasena K. Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev. 2011;31(4):483–519. doi:10.1002/med.20187
   PubMed Web of Science ®Google Scholar
• Benarroch EE. Monoamine transporters. Structure Regulation Clin Implications. 2013;81(8):761–768.
   Google Scholar
• Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461–2470. doi:10.1080/14656566.2016.1258063
   PubMed Web of Science ®Google Scholar
• Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006;6(1):7–17. doi:10.1586/14737175.6.1.7
   PubMedGoogle Scholar
• Reserpine [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Available from: https://www.ncbi.nlm.nih.gov/books/NBK557767/. Accessed November 17, 2023.
   Google Scholar
• Termsarasab P. Chorea. Continuum. 2019;25(4):1001–1035. doi:10.1212/CON.0000000000000763
   PubMedGoogle Scholar
• Citrome L. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018;18(4):323–332. doi:10.1080/14737175.2018.1455504
   PubMed Web of Science ®Google Scholar
• Niemann N, Jankovic J. Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019;42(2):37–41. doi:10.1097/WNF.0000000000000326
   PubMed Web of Science ®Google Scholar
• Heo Y-A, Scott LJ. Deutetrabenazine: a Review in Chorea Associated with Huntington’s Disease. Drugs. 2017;77(17):1857–1864. doi:10.1007/s40265-017-0831-0
   PubMed Web of Science ®Google Scholar
• Sampaio C, Borowsky B, Reilmann R. Clinical trials in Huntington’s disease: interventions in early clinical development and newer methodological approaches. Mov Disorders. 2014;29(11):1419–1428. doi:10.1002/mds.26021
   PubMed Web of Science ®Google Scholar
• Citrome L. Deutetrabenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication—What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017;71(11):46.
   Web of Science ®Google Scholar
• Richard A, Frank S. Deutetrabenazine in the treatment of Huntington’s disease. Neurodegener Dis Manag. 2019;9(1):31–37. doi:10.2217/nmt-2018-0040
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019;90(12):1317–1323. doi:10.1136/jnnp-2018-319918
   PubMedGoogle Scholar
• Testa CM, Jankovic J. Huntington disease: a quarter century of progress since the gene discovery. J Neurol Sci. 2019;396:52–68. doi:10.1016/j.jns.2018.09.022
   PubMed Web of Science ®Google Scholar
• Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers. 2015;1(1):15005.
   PubMedGoogle Scholar
• Frank S, Testa CM, Stamler D; Huntington Study Group. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: a Randomized Clinical Trial. JAMA. 2016;316(1):40–50. doi:10.1001/jama.2016.8655
   PubMed Web of Science ®Google Scholar
• Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ. Tetrabenazine Versus Deutetrabenazine for Huntington’s Disease: twins or Distant Cousins? Movement Disorders Clin Practice. 2017;4(4):582–585. doi:10.1002/mdc3.12483
   PubMed Web of Science ®Google Scholar
• Claassen DO, Carroll B, De Boer LM, et al. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. J Clin Mov Disord. 2017;4(3). doi:10.1186/s40734-017-0051-5
   PubMedGoogle Scholar
• Frank S, Testa CM, Stamler D, et al. Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: results From the ARC-HD Open-label Study. CNS Spectr. 2021;26(2):164–165. doi:10.1017/S1092852920002655
   Google Scholar
• Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366–372. doi:10.1212/01.wnl.0000198586.85250.13
   PubMed Web of Science ®Google Scholar
• Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci. 2018;389:10–16. doi:10.1016/j.jns.2018.02.008
   PubMed Web of Science ®Google Scholar
• Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: a Meta-Analysis. J Clin Psychiatry. 2017;78(3):e264–e78. doi:10.4088/JCP.16r10832
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003–2010. doi:10.1212/WNL.0000000000003960
   PubMed Web of Science ®Google Scholar
• Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595–604. doi:10.1016/S2215-0366(17)30236-5
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Serbin M, Yonan C. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. J Comp Eff Res. 2019;8(13):1077–1088. doi:10.2217/cer-2019-0059
   PubMed Web of Science ®Google Scholar